We describe a new method for the simultaneous assay of 3,4-dihydroxyphenylalanine (L-dopa) and dopamine in serum. Both compounds have been determined quantitatively at concentrations as low as 10 ag/liter with a coefficient of variation of less than 4%. Peak heights were linearly related to concentration up to 10 mg/liter for each compound. Assay of human sera gave within-run and day-to-day coefficients of variation of 2.8% and 3.1% for L-dOpa, and 2.9% and 3.7% for dopamine. The linear relationship between readings (nA, y-axis)and concentration (ag/liter) is described by the following equations: y = (21.0 ± 0.082)x + (0.46 0.31 SD) for L-dopa and y = (17.0 J 0.10)x + (0.08 ± 0.04 SD) for dopamine. The procedure combines liquid/solid extraction, liquid chromatography, and controlled-potential electrochemistry. The simplicity, sensitivity, and accuracy of this method make it suitable for routine clinical analysis of serum samples to optimize bioavailability for individual patients. After the extraction procedure is completed, samples can be analyzed atthe rateof 10/h.
Materials and Methods

Reagents
Group, 8738 Oakwood Ave., Hesperia, Calif. 92345; Model 232CX). Water was circulated through a jacket (Altex, Model 251-10) surrounding the column to maintain a temperature of 28 #{176}C. The mobile phase was pumped at a rate of 0.40 mi/mm. The detector potential was set at +0.72 V vs. an Ag/AgCl reference electrode.
Procedure Place 1 ml of blood serum, 3.5 ml of saturated sodium chloride solution, and 100 l of concentrated hydrochloric acid in a 15-ml polypropylene centrifuge tube. Shake well and centrifuge for 15 mm at 15 000 X g to precipitate the protein. Pour the supernate into a 12-mi glass centrifuge tube. Hydrolyze sulfate conjugates by heating in a 90 #{176}C water bath for 20 mm. Cool the tubes and then add 0.5 g of ammonium sulfate. Extract twice with ethyl acetate and once with hexane (5-mi portions of each). Centrifuge briefly, aspirate, and discard the nonaqueous layers.
Place the aqueous layer in a 10-ml beaker with a magnetic stirrer. Add 100 l of both the ethylenediaminetetraacetate and the sodium metabisulfite solutions. While stirring the mixture, adjust the pH to 8.5 ± 0.1 by rapid addition of 3 mol/liter sodium hydroxide and then 1 mol/liter sodium hydroxide. Shake with 60 mg of acid-washed alumina in a 5-mi conical screw-cap vial (Pierce Chemical Co., Box 117, Rockford, Ill. 61105; Reacti-Vials) for 12 mm. Allow the alumina to settle and then aspirate and discard the serum solution. Wash the alumina once with the phosphate buffer and twice with distilled water. Dry the alumina in a vacuum oven for 10 mm at 40 #{176}C.
Elute the L-dopa and dopamine from the alumina with 300 ,d of 1 mol/liter acetic acid. Gently shake the vials for 10 mm on a mechanical shaker. Transfer about 200 tl of the eluent to a second vial. Inject 20 il of this solution onto the chromatographic column. Measure the peak heights and calculate the concentrations by comparison with the peak heights obtained for the working standard containing a known concentration (1 mg/liter) of L-dopa and dopamine. is lower than is normally expected for a therapeutic dose and because most previous methods have a detection limit of about 1 mg/liter. Because the amount of L-dopa present in the blood of Parkinson's disease patients on L-dopa therapy is frequently about 1 mg/liter (2), it is desirable to be able to measure lower concentrations, particularly for pharmacokinetic studies. The present method permits measurements down to 10 pg/liter with a precision of better than ±4%. In addition, dopammne can be quantitated simultaneously down to the same limit, which makes the method well suited to following the efficacy of decarboxylase inhibitors. This latter capability is unique to the present assay. The two dopamine sulfate esters cannot yet be monitored directly and thus a hydrolysis procedure is necessary, to establish the total dopamine present. These esters are known to constitute a major part of the serum dopamine (17).
Results and Discussion
We know of no probable endogenous interferences with this assay, because of the highly specific combination of liquid chromatography and electrochemistry. We are now using the method routinely for clinical samples. Very similar procedures have been devised for monitoring other catechol-based drugs in serum (e.g., a-methyl dopa and carbidopa).
We believe that the approach described here has general applicability to compounds of this type, although slight modifications in conditions may be necessary to optimize the assay for a particular drug. Other commercial column packings (e.g., Du Pont "Zipax SCX") than that used here will improve the resolution in certain situations. For example, when both carbidopa and L-dopa are administered together, they are better resolved with Zipax SCX as the stationary phase. Table 1 summarizes precision and recovery data for the assay. The linear relation between readings and concentration was tested by adding standard amounts of each compound to the serum pool over a range from 50 ag/liter to 10 mg/liter and analyzing. The linear response in nanoamperes (y) vs. iig/liter (x) is described by the following equations: y = (21.0 ± 0.082)x + (0.46 ± 0.31 SD) for L-dopa and y = (17.0 ± 0.10)x + (0.08 ± 0.04 SD) for dopamine.
After the extraction procedure is completed, samples can be analyzed at the rate of 10 per hour. 
